In Rio de Janeiro this week, Winnie Byanyima stood before the International Aids Conference and described the effect of withdrawn American funding in language usually reserved for acts of violence. Elon Musk had claimed the cuts made under his stewardship of DOGE cost nobody their life. The UNAIDS executive director's rebuttal was blunt: HIV does not kill the way a bullet does, but the slow unravelling of treatment and prevention programmes amounts, in her words, to a death sentence delivered gradually. The statistics supporting such claim are striking. International financing for HIV fell by more than a billion and a half dollars last year, an eighteen per cent contraction to its lowest level in nearly two decades, even as scientific progress against the disease has never moved faster.

That juxtaposition, breakthrough medicine arriving just as the money to deliver it disappears, is usually framed as a story about American retrenchment and the developing world. It is worth asking what it looks like closer to home, because Britain is living through its own version of the same problem, expressed through a different mechanism entirely.

Lenacapavir, the twice-yearly injectable that UNAIDS describes as offering vaccine-like protection against HIV, received MHRA approval for prevention use in February. NICE is now conducting the cost-effectiveness appraisal that will determine whether the NHS actually funds it. Cabotegravir, a similar long-acting option, has already been approved for NHS use in Scotland through the Scottish Medicines Consortium, while England and Wales continue to wait on a NICE decision that has stretched across years rather than months. Meanwhile, the separate access programme that had quietly supplied lenacapavir to a small number of patients with multi-drug-resistant HIV closed to new referrals after NHS England and the manufacturer spent more than two years unable to agree a price, with no indication of when or whether negotiations will resume.

None of this stems from a funding cut in the way Byanyima means it. Nobody in Whitehall has announced a reduction in HIV spending. What has happened instead is slower and less visible: a regulatory and commercial machinery that takes so long to convert approval into access that the practical effect, for the patient waiting on a decision, is barely distinguishable from a cut. The drug exists. The evidence is settled. What is missing is the administrative capacity to translate that into a prescription, at a price the system will pay, on a timeline that matters to someone at risk of infection today rather than in three years' time.

There is a second, related fragility. HIV prevention services in England sit largely outside NHS England's own commissioning remit, funded instead through local authorities whose public health budgets have been squeezed for the better part of a decade. UNAIDS's global report makes the same point about the wider epidemic: treatment services tend to survive funding shocks longest, while prevention, the less visible, less politically rewarded end of the system, is what erodes first. Sexual health clinics facing repeated in-year budget pressure are not a world away from the collapsing prevention infrastructure the report describes in donor-dependent countries. The mechanism differs. The pattern does not.

None of this excuses the scale of what has happened through PEPFAR's contraction, where genuine funding withdrawal has closed treatment sites and left tens of thousands of children without therapy they had been receiving the year before. That is a different order of harm, driven by an actual reduction in money rather than a failure to spend it well. But Rachel Reeves's Treasury and Wes Streeting's Department of Health and Social Care should not take comfort in the distinction. A health system that possesses the money but still cannot move at the speed of its own science has simply relocated the failure rather than avoided it. The lesson from Rio is not only about what happens when funding disappears. It is also about what happens when it does not disappear, and the system still cannot keep pace with what medicine has already made possible.